Headed to Drug Discovery USA in Boston on June 16-17? Connect with our drug design and cell line development experts, John Gill and Keith Cannon while you’re there.  Swing by our booth #4 to discuss your project-specific needs with John & Keith and discover how our fully integrated, end-to-end capabilities can streamline and de-risk your program to IND and beyond.

Event Overview

Recent advances in chemical biology and protein engineering are expanding the boundaries of which proteins can be modulated pharmacologically. Multifunctional small molecules (such as molecular glues, targeted protein degraders, and allosteric modulators) are enabling precise control over protein stability, localization and activity, often by exploiting endogenous cellular pathways.

In parallel, novel biologic modalities, including engineered antibodies, multi-specific binders, peptide scaffolds, nucleotide and RNA therapeutics, offer complementary strategies to engage complex or transient target surfaces with high affinity and specificity. Collectively, these approaches are reshaping early‑stage drug discovery by providing versatile platforms to modulate challenging targets through mechanisms beyond simple inhibition.

Furthermore, hybrid strategies that integrate small molecules with biologics, such as antibody–drug conjugates (ADCs) and chemically enhanced biologics, are demonstrating synergistic potential. Together, these emerging technologies highlight a rapidly evolving therapeutic landscape in which difficult to drug targets are increasingly accessible, opening new avenues for disease intervention and precision medicine. Continued innovation in molecular design, delivery, and mechanistic understanding will be critical to fully realize the promise of these next‑generation modalities.

Schedule a Meeting with Our Experts